News & Updates

IMT Company News & Updates

IMT News (Posted 15/Nov/2025) – IMT announced that it has resolved a legal dispute over the contract agreement regarding the assignment of IP rights that enables to IMT to resume all its engagement with potential investors going forward. ENDS

 IMT News (Posted 06/Mar/2022) – IMT would like to disclose that it has been engaging in a legal dispute with 2 entities over the contract agreement regarding the assignment of IP rights.  The matter is currently in a NSW Supreme Court proceeding and therefore IMT has suspended all its engagement with potential investors until further notice. ENDS

IMT News (Posted 06/Mar/2021) – IMT is proud to announce the publication of our scientific review articles summarizing our research findings and independent corroborating evidence titled “The Therapeutic Implications of Activated Immune Responses via the Enigmatic Immunoglobulin D” in the peer-reviewed journal International Reviews of Immunology and our review of evidence for the scientific rational of anti-IgD antibody titled “Harnessing Newton’s 3rd Law Paradigm to Treat Autoimmune Diseases and Chronic Inflammation” in the journal Inflammation Research.  Please visit our Research Publications for more details.  ENDS

IMT News (Posted 30/Oct/2018) – IMT has recently received an expression of interest from a specialist private equity fund.  IMT is currently engaged in ongoing discussions regarding potential funding partnerships and the current state of IP ownership with the private equity firm and a number of angel investors.  ENDS

IMT News (Posted 25/Sept/2018) – IMT is proud to announce that the latest research finding of the therapeutic effects of anti-IgD mAb treatment on experimental allergic skin inflammation models by our IMT scientist has been accepted for publication in the peer-reviewed journal Immunology Letters.  Please visit our Research Publications for more details.  ENDS

BioPharma Industry News

Industry News (Posted 21/Sept/2020) – Chemodrug-conjugated anti-CD79b mAb (Polatuzumab) has been approved by US FDA and Australian TGA for the treatment of refractory diffuse large B-cell lymphoma.

Industry News (Posted 13/Sept/2018) – Notable Licensing Deals In The Biopharmaceutical Industry in Q3 2017.

Industry News (Posted 11/Sept/2018) – Global Monoclonal Antibody Therapeutics Market Will Reach US$ 218.97 Billion by 2023: Zion Market Research.